S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Improve Mental Health Next Year by Breaking 17 Financial Rules
Millionaire Investor Reveals: “How I Made My Second Fortune… By Avoiding 99% of Stocks” (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Can ZIM Defy Broad Downturn In The Container Shipping Industry?
China fines former NBA star Lin over quarantine comments
The single greatest medical breakthrough of all time? (Ad)
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Improve Mental Health Next Year by Breaking 17 Financial Rules
Millionaire Investor Reveals: “How I Made My Second Fortune… By Avoiding 99% of Stocks” (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Can ZIM Defy Broad Downturn In The Container Shipping Industry?
China fines former NBA star Lin over quarantine comments
The single greatest medical breakthrough of all time? (Ad)
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Improve Mental Health Next Year by Breaking 17 Financial Rules
Millionaire Investor Reveals: “How I Made My Second Fortune… By Avoiding 99% of Stocks” (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Can ZIM Defy Broad Downturn In The Container Shipping Industry?
China fines former NBA star Lin over quarantine comments
The single greatest medical breakthrough of all time? (Ad)
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Improve Mental Health Next Year by Breaking 17 Financial Rules
Millionaire Investor Reveals: “How I Made My Second Fortune… By Avoiding 99% of Stocks” (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Can ZIM Defy Broad Downturn In The Container Shipping Industry?
China fines former NBA star Lin over quarantine comments
The single greatest medical breakthrough of all time? (Ad)
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
LON:PRTC

PureTech Health - PRTC Share Forecast, Price & News

GBX 294
+7.50 (+2.62%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
284
297
50-Day Range
212.28
291.99
52-Week Range
145.80
305
Volume
270,353 shs
Average Volume
323,172 shs
Market Capitalization
£819.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
GBX 580
PRTC stock logo

About PureTech Health (LON:PRTC) Stock

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia. In addition, the company is developing drug delivery platform for oral administration of proteins, peptides, and other difficult-to-deliver payloads; products to generate new human hair follicles and hair; drug delivery platform for drugs that treat inflammation and associated disorders; platform to address immunosenescence; novel targeted immunotherapies for cancer; monoclonal antibodies for immuno-suppressive gamma delta T cells in pancreatic and colorectal cancers, and other solid tumors; novel approaches to enhance delivery and distribution of therapeutics; and digital health technologies, as well as engages in enhancing health through food through the creation of nutrition technology. Further, it is developing a platform and products that take in physiological data from sensors and correlates that data with musical data components; voice-based tools for passive assessment and tracking of patient health; commensal organism-based products for enhancing human health; and technology platform to identify experts in healthcare and other research-based disciplines, as well as engages in identifying healthcare expert networks and reviewing their conversations and content on social media. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Receive PRTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PureTech Health and its competitors with MarketBeat's FREE daily newsletter.

PRTC Stock News Headlines

PureTech Announces Share Buyback Program Update
PureTech Founded Entity Akili Announces PLOS ONE...
PureTech Health PLC : PRTC Provides Recap Ahead of Catalyst-Rich 2022
PureTech Health PLC : PRTC's Gelesis Receives $30M Plenity Order from Ro
See More Headlines
Receive PRTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PureTech Health and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
300
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
GBX 580
High Stock Price Forecast
GBX 580
Low Stock Price Forecast
GBX 580
Forecasted Upside/Downside
+97.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£18.58 million
Cash Flow
GBX 139.04 per share
Book Value
GBX 203 per share

Miscellaneous

Free Float
N/A
Market Cap
£819.60 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Ms. Daphne Zohar (Age 47)
    Founder, CEO & Exec. Director
  • Dr. Bennett M. Shapiro (Age 78)
    Co-Founder & Non-Exec. Director
  • Dr. Robert S. Langer Jr. (Age 69)
    Co-Founder, Non-Exec. Director & Member of Scientific Advisory Board
  • Mr. Stephen M. Muniz J.D. (Age 48)
    COO, Exec. VP of Legal & Operations, Sec. and Exec. Director
  • Dr. Bharatt M. Chowrira (Age 53)
    Pres and Chief of Bus. & Strategy













PRTC Stock - Frequently Asked Questions

Should I buy or sell PureTech Health stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PureTech Health in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRTC shares.
View PRTC analyst ratings
or view top-rated stocks.

What is PureTech Health's stock price forecast for 2023?

1 equities research analysts have issued 12 month price targets for PureTech Health's shares. Their PRTC share price forecasts range from GBX 580 to GBX 580. On average, they anticipate the company's stock price to reach GBX 580 in the next year. This suggests a possible upside of 97.3% from the stock's current price.
View analysts price targets for PRTC
or view top-rated stocks among Wall Street analysts.

How have PRTC shares performed in 2022?

PureTech Health's stock was trading at GBX 292 at the beginning of the year. Since then, PRTC shares have increased by 0.7% and is now trading at GBX 294.
View the best growth stocks for 2022 here
.

What other stocks do shareholders of PureTech Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PureTech Health investors own include Nemaska Lithium (NMX), Yamana Gold (YRI), Asanko Gold (AKG), Arotech (ARTX), Boeing (BA), Baozun (BZUN), Chaarat Gold (CGH), Eldorado Gold (ELD), CarMax (KMX) and Knowles (KN).

What is PureTech Health's stock symbol?

PureTech Health trades on the London Stock Exchange (LON) under the ticker symbol "PRTC."

How do I buy shares of PureTech Health?

Shares of PRTC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is PureTech Health's stock price today?

One share of PRTC stock can currently be purchased for approximately GBX 294.

How much money does PureTech Health make?

PureTech Health (LON:PRTC) has a market capitalization of £819.60 million and generates £18.58 million in revenue each year.

How many employees does PureTech Health have?

The company employs 300 workers across the globe.

How can I contact PureTech Health?

PureTech Health's mailing address is 501 Boylston St Ste 6102, BOSTON, MA 02116-3769, United States. The official website for the company is puretechhealth.com. The company can be reached via phone at +1-617-4822333.

This page (LON:PRTC) was last updated on 12/3/2022 by MarketBeat.com Staff